Akari Therapeutics Plc AKTX
are an oncology company developing next-generation antibody-drug conjugates ("ADCs") built around novel, proprietary
payloads utilizing powerful biology to attack cancer. Our lead payload, PH1, targets RNA splicing by modulating the spliceosome, a
complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and
growth. PH1's disruption of normal RNA splicing has multiple modes of action on cancer cells: 1) cell killing and
AKTX is a depositary receipt: one AKTX stands for 2,000 shares of this company, per the cover page of its latest 10-K. The market cap and the multiples above are stated per receipt; the statements below, including EPS, are as filed and are per underlying share.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $367.9K | $607.7K | — | — | — | — | — | — |
| R&D | $2.8M | $7.0M | $5.5M | $3.9M | $9.1M | $8.8M | $8.7M | $11.8M | $23.3M | $17.3M |
| SG&A | $9.3M | $9.7M | $11.4M | $8.5M | $8.1M | $9.2M | $8.2M | $11.7M | $11.8M | $9.9M |
| Total operating expenses | $17.3M | $21.6M | $16.8M | $12.5M | $17.2M | $18.0M | $17.0M | $20.8M | $37.8M | $27.2M |
| Operating income | -$17.3M | -$21.6M | -$16.8M | -$11.8M | -$17.2M | -$18.0M | -$17.0M | -$20.8M | -$37.8M | -$27.2M |
| Interest expense | $100.0K | $244.0K | — | — | — | — | — | — | $0 | $0 |
| Pre-tax income | -$18.3M | -$19.8M | -$10.0M | -$13.2M | -$17.4M | -$17.1M | -$16.8M | -$20.5M | -$35.4M | -$18.1M |
| Income tax | $1.0M | $0 | $0 | $74.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$17.3M | -$19.8M | -$10.0M | -$13.1M | -$17.4M | -$17.1M | -$16.8M | -$20.5M | -$35.4M | -$18.1M |
| EPS, basic | 0.00 | 0.00 | 0.00 | -0.74 | 0.00 | -0.01 | -0.01 | — | — | — |
| EPS, diluted | 0.00 | 0.00 | 0.00 | -0.74 | 0.00 | -0.01 | -0.01 | -0.01 | -0.03 | -0.02 |
| Shares, diluted (wtd. avg.) | 67.33B | 23.89B | 9.79B | 17.7M | 4.29B | 3.16B | 1.83B | 1.54B | 1.25B | 1.18B |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $0 | $0 | $3.8M | $13.2M | $9.4M | $14.1M | $5.7M | $6.0M | $28.2M | $34.2M |
| Short-term investments | — | — | — | — | — | — | — | — | $0 | $10.0M |
| Total current assets | $5.5M | $3.0M | $4.3M | $13.8M | $11.6M | $14.6M | $4.6M | $8.0M | $28.8M | $45.6M |
| Property, plant and equipment | — | — | — | $0 | $0 | $0 | $12.1K | $15.8K | $55.9K | $58.4K |
| Goodwill | $8.4M | $8.4M | — | — | — | — | — | — | — | — |
| Other intangibles | — | — | $14.0K | $17.0K | $22.9K | $27.1K | $31.1K | $32.9K | $39.1K | $39.4K |
| Total assets | $47.9M | $50.6M | $4.4M | $13.8M | $11.6M | $14.6M | $4.6M | $8.2M | $29.1M | $45.9M |
| Accounts payable | $8.8M | $12.4M | $1.7M | $947.0K | $1.8M | $3.4M | $1.5M | $1.8M | $2.0M | $2.2M |
| Total current liabilities | $12.4M | $19.9M | $4.6M | — | — | — | — | $4.9M | $11.8M | $11.7M |
| Total liabilities | $19.6M | $28.3M | $4.6M | $12.0M | $6.1M | $5.2M | $4.2M | $3.4M | $11.9M | $11.8M |
| Retained earnings | -$264.6M | -$247.3M | -$227.5M | -$217.5M | -$199.7M | -$182.3M | -$154.5M | -$148.5M | -$110.3M | -$74.9M |
| Total equity | $28.3M | $22.2M | -$229.0K | $1.8M | $5.6M | $9.4M | $7.6K | $4.4M | $22.2M | $34.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.6M | -$12.6M | -$16.4M | -$7.5M | -$18.8M | -$17.0M | -$12.9M | -$22.8M | -$31.6M | -$24.6M |
| Depreciation and amortisation | — | $14.0K | $4.0K | $151.9K | $4.1K | $8.9K | $19.2K | $35.8K | $42.4K | $39.9K |
| Stock-based compensation | $2.9M | $2.2M | $1.1M | $560.1K | $314.6K | $325.5K | $1.0M | $1.6M | $2.7M | $3.9M |
| Capital expenditure | — | — | $0 | $142.2K | — | — | $0 | $0 | $36.9K | $54.8K |
| Investing cash flow | — | $382.0K | $0 | -$142.2K | — | — | $0 | $0 | $10.0M | -$10.1M |
| Financing cash flow | $13.2M | $11.0M | $7.0M | $8.1M | $14.3M | $25.1M | $12.6M | $500.0K | $15.7M | $0 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-027279.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $607.7K | $367.9K | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$18.1M | -$35.4M | -$20.5M | -$16.8M | -$17.1M | -$17.4M | -$13.1M | -$10.0M | -$19.8M | -$17.3M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Material agreement signed Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote Item 5.07
- Material agreement signed Item 1.01
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Unregistered share sale Item 3.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |